Published in Biotech Law Weekly, August 5th, 2005
The new patent ("Modified vaccinia ankara virus variant" - U.S. Patent No. 6,913,752) grants claims that are directed to an MVA-based vaccinia virus having specific improved properties, such as that it does not replicate in human cells, compared to other MVA strains which may replicate in certain human cells.
This new patent, as well as the USPTO patent received by the company on MVA-BN in 2004, are based on the same patent priority from a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.